within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonSteroids.M01AX13_Proquazone;

model Proquazone
  extends Pharmacolibrary.Drugs.ATC.M.M01AX13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M01AX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Proquazone is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It was previously used for the treatment of rheumatic disorders, arthritis, and musculoskeletal pain, but is not approved or marketed in most countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult based on related NSAIDs and structural analogs; no direct human pharmacokinetic publication available for proquazone.</p><h4>References</h4><ol><li><p>Hinderling, PH, &amp; Roos, A (1984). Pharmacokinetics of the antirheumatic proquazone in healthy humans. <i>Journal of pharmaceutical sciences</i> 73(3) 332–340. DOI:<a href=\"https://doi.org/10.1002/jps.2600730312\">10.1002/jps.2600730312</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6716240/\">https://pubmed.ncbi.nlm.nih.gov/6716240</a></p></li><li><p>Nimmerfall, F, &amp; Rosenthaler, J (1980). Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. <i>Journal of pharmaceutical sciences</i> 69(5) 605–607. DOI:<a href=\"https://doi.org/10.1002/jps.2600690538\">10.1002/jps.2600690538</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6770075/\">https://pubmed.ncbi.nlm.nih.gov/6770075</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Proquazone;
